Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review
Authors:
- Adrian Yun-San YipAYAdrian Yun-San Yip
- Lap-Ah TseLTLap-Ah Tse
- Eleanor Yuen-Yuen OngEOEleanor Yuen-Yuen Ong
- Louis Wing-Cheong ChowLCLouis Wing-Cheong Chow
- 1 June 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 21 (5) , 487-493
Abstract
Breast cancer is the second cause of cancer mortality worldwide and there is an unmet need for novel anticancer agents. Lapatinib is a novel tyrosine kinase inhibitor for treatment of breast cancer with human epidermal growth factor receptor 2 (HER2) amplification. Given promising results in clinical studies, we investigated the survival benefits of lapatinib use in patients with HER2-overexpressing advanced or metastatic breast cancer. We searched MEDLINE, EMBASE, American Society of Clinical Oncology Meeting proceedings, San Antonio Breast Cancer Symposia proceedings, and the Cochrane Library between 2000 and 2008 for randomized controlled trials where lapatinib was used as single agent or in combination with or following other therapies. Three trials (n=704) met the inclusion criteria. Study quality was assessed by two independent reviewers and meta-analyses were conducted. Significant differences were observed between lapatinib-containing treatments to those without lapatinib in terms of survival. Pooled estimates suggested the hazard ratios of 0.61 [95% confidence interval (CI): 0.50–0.74] for progression-free survival and 0.76 (95% CI: 0.60–0.97) for overall survival. Objective response rate and clinical benefit rate also showed significant differences in favoring the use of lapatinib with odds ratios of 2.15 (95% CI: 1.48–3.11) and 2.23 (95% CI: 1.59–3.12), respectively. Heterogeneity between studies was not observed. In conclusion, addition of lapatinib to conventional anticancer treatment might offer superior survival benefit to patients with advanced metastatic HER2-overexpressing breast cancer. Further investigations on the use of lapatinib in combination with anticancer agents are warranted.Keywords
This publication has 32 references indexed in Scilit:
- Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain MetastasesAmerican Journal of Therapeutics, 2009
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005
- HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast CancerJournal of Clinical Oncology, 2003
- Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heartSeminars in Oncology, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987